Army awards contract for biodefense development

PPD, Inc., a global contract research organization, announced on Tuesday that it has been awarded the U.S. Army Medical Research Acquisition Activity: Regulatory Affairs & Compliance Support contract for biodefense and vaccine development.

The multi-year, indefinite delivery, indefinite quantity contract has a ceiling value of $45.5 million over a five year period beginning April 15. PPD has collaborated on over 900 government and public health development projects, including infectious diseases, autoimmune and asthma/allergic diseases, vaccines and biodefense.

PPD said that using its strong operational regulatory capacity, an in-depth understanding of global regulatory requirements and submission strategies, and regulatory consulting experience will aid the U.S. Army in the preparation and filing of clinical trial submissions to the U.S. Food and Drug Administration and other regulatory authorities. The company said it will ensure regulatory compliance for the U.S. Army’s clinical programs and will support biodefense, biopreparedness and vaccine development initiatives that are aimed at protecting military personnel.

“This contract enables us to deliver on our breadth of global regulatory and biostatistics services and assist the U.S. Army in advancing clinical programs that improve the health of men and women serving in our armed forces,” Henrietta Ukwu, the senior vice president of global regulatory affairs for PPD, said. “We are pleased to partner with the U.S. Army in this effort and to continue to extend our long history of partnering with the U.S. Government on clinical research and development.”